What is Anika Therapeutics's latest dividend and current dividend yield?

What factors drove the changes in Anika Therapeutics's revenue and profit?

What is Anika Therapeutics's gross profit margin?

What were the key takeaways from Anika Therapeutics’s earnings call?

What is the revenue and EPS growth rate for Anika Therapeutics year over year?

Did Anika Therapeutics beat or miss consensus estimates last quarter?

What guidance did Anika Therapeutics's management provide for the next earnings period?

What were the key takeaways from Anika Therapeutics's earnings call?

- **Commercial Channel Dominance**: 15% FY2025 commercial revenue growth (22% Q4) driven by international OA pain and Integrity, offsetting OEM decline.
- **Pipeline Momentum**: Hyalofast FDA engagement, Cingal NDA on track, Integrity post-market study 50% enrolled with $6M FY2025 revenue.
- **Financial Strength**: 63% Q4 gross margin, $11.2M operating cash flow, $57.5M ending cash; 2026 EBITDA target 5%-10% of revenue.
- **Sustainability Focus**: High 50s% gross margin target, $2.5M annualized G&A savings, and $10.7M share buyback completion by Q2 2026.

**【CEO Strategic Priorities】**
- **Commercial Channel Growth**: Focus on international OA pain management and Integrity, achieving 22% Q4 and 15% FY25 commercial revenue growth. OEM channel declined 12% Q4/17% FY25 due to U.S. pricing pressures.
- **Innovation Pipeline Progress**: Hyalofast PMA submission with FDA engagement; Cingal nearing U.S. NDA with bioequivalence study underway; Integrity post-market study 50% enrolled.
- **Operational Excellence**: 63% Q4 gross margin (vs. 56% prior year) driven by manufacturing efficiency; $11.2M FY25 operating cash flow; $57.5M ending cash balance.

**【CFO Financial Highlights】**
- **Q4 2025 Results**: $30.6M revenue (flat YoY), $13.3M commercial (22% growth), 63% GAAP gross margin. Adjusted EBITDA $4.5M vs. $3.8M prior year.
- **FY2025 Performance**: $112.8M revenue (-6% YoY), $48.4M commercial (15% growth). GAAP gross margin 57% (vs. 63% prior year). Operating cash flow improved 110% to $11.2M.
- **2026 Guidance**: Total revenue $114M-$122.5M (1%-9% growth). Adjusted EBITDA 5%-10% of revenue, driven by commercial channel expansion and cost savings.

**【Q&A Key Highlights】**
- **Hyalofast Outlook**: $3M U.S. revenue potential in 2027 if approved; international Hyalofast sales contributing $5.2M FY25 R&D investment.
- **Gross Margin Target**: High 50s% sustainable over time, with Q4 63% margin as illustrative peak.
- **Free Cash Flow**: Expect FY2026 cash flow similar to FY2025, supported by $10.7M share buyback completion by Q2 2026.
- **Integrity Growth**: Q4 2025 revenue $6M (20% sequential growth); targeting double-digit 2026 expansion with new sizes driving adoption beyond shoulder procedures.
- **Capital Allocation**: Prioritize manufacturing investment and U.S. sales channel; no immediate M&A plans.


Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript

- **Commercial Channel Dominance**: 22% YoY growth in Commercial Channel offsets OEM decline, driven by Integrity's 25% YoY procedure growth and international expansion.
- **Product Pipeline Progress**: Hyalofast PMA submission completed; Cingal bioequivalence study initiation on track for late 2025. Over 1 million Cingal injections globally.
- **Financial Discipline**: 12% YoY SG&A reduction and $6.9M operating cash flow highlight cost control. $15M share buyback announced.
- **Growth Catalysts**: New Integrity SKUs launching in Q4; Hyalofast FDA engagement expected; Cingal U.S. launch timeline hinges on bioequivalence study completion.

**【Management Opening Remarks】**
- Anika reported Q3 2025 revenue of $27.8 million, down 6% YoY, driven by J&J's pricing pressure in the OEM channel. Commercial Channel revenue grew 22% YoY to $12 million, offsetting OEM declines.
- The company reaffirmed its focus on cost control, with SG&A expenses down 12% YoY and operating expenses down 3%.
- A second $15 million share repurchase program was announced, reflecting capital return priorities.

**【CEO Commentary】**
- **Commercial Channel Momentum**: Integrity Implant system delivered 25% YoY growth, with 500 procedures performed in Q3 and 300 surgeon users. New SKUs for hip, knee, and ankle applications are being rolled out.
- **Regulatory Progress**: Hyalofast PMA submission completed, with Phase III FastTRACK study showing clinically meaningful improvements in pain and function. Cingal bioequivalence study initiation on track for late 2025.
- **International Expansion**: Hyalofast and Cingal achieved 21% YoY growth in international OA Pain Management, with Cingal surpassing 1 million injections globally.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Commercial Channel ($12M, +22% YoY) offset OEM Channel decline (-20% YoY) due to J&J pricing pressure. Monovisc unit volume up 11% YoY, but average price down 17%.
- **Gross Margin**: 56% in Q3, down 10ppt YoY due to lower J&J sales, but up 5ppt sequentially from production recovery.
- **Operating Expenses**: Total OpEx $18.8M (-3% YoY), with R&D up 17% due to Cingal pre-filing costs. Adjusted EBITDA $0.9M, breakeven vs. prior guidance.
- **Cash Flow**: Operating cash flow $6.9M (+38% YoY), with $58M cash on hand and no debt.

**【Q&A Highlights】**
- **Integrity Growth Strategy**: Equal focus on new surgeon training and existing surgeon adoption, with 60% of users performing multiple cases. Q4 SKUs expansion expected to accelerate adoption.
- **Cingal Timeline**: Bioequivalence study start by end-2025, with NDA filing dependent on study completion. Toxicity study completion in Q1 2026.
- **Capital Allocation**: Prioritize internal investments (e.g., Integrity, Hyalofast) > CapEx > share buybacks. No M&A plans.
- **Production Issues**: Q3 disruptions resolved, with capacity restored by year-end. Gross margin expected to stabilize near 55-60% range, excluding J&J pricing volatility.

Anika Therapeutics, Inc. (ANIK) Q3 2025 Earnings Call Transcript

- **Integrity Outperforms**: Regenerative solutions revenue up 41% YoY, Integrity on track to double in 2025 with new SKUs targeting $40M market.
- **Hyalofast Delayed**: FDA submission planned for Q4 2025, but commercial launch pushed to 2027 due to clinical trial challenges.
- **Gross Margin Recovery**: H2 2025 margin expected at 58-59%, driven by resolved manufacturing issues, but J&J pricing pressures persist.
- **Cost Control**: 17% YoY reduction in operating expenses, maintaining strong liquidity with $53M cash.

**【CEO Summary Section】**
- **Hyalofast Clinical Trial Update**: Missed primary endpoints due to microfracture arm challenges and COVID-related data loss, but showed consistent improvement over comparator. Submission of full data package to FDA planned for Q4 2025, with commercial launch delayed to 2027.
- **Integrity Growth**: Regenerative solutions revenue up 41% YoY, Integrity on track to more than double in 2025. New SKUs for foot/ankle procedures launched in limited release, targeting $40M addressable market.
- **Financial Overview**: Q2 revenue $28.2M (-8% YoY), regenerative solutions +41% YoY. Operating expenses down 17% YoY, adjusted EBITDA flat at -$200K.

**【CFO Financial Commentary】**
- **Gross Margin Dynamics**: Q2 gross margin 51% (-16ppt YoY) due to $3M one-time manufacturing charge. Excluding charge, margin >60%. Guidance for 58-59% in H2 2025, with full year margin impacted by J&J pricing and Cingal costs.
- **Channel Performance**: Commercial channel ($11.9M flat YoY) driven by Integrity growth, offset by 10% decline in international OA Pain. OEM channel ($16.3M -13% YoY) reflects J&J pricing pressure.
- **Cash Position**: $53M cash on hand, $1.4M Q2 capex for MA facility expansion. No debt, no capital raise needed.

**【Q&A Highlights】**
- **Gross Margin Outlook**: H2 2025 improvement driven by resolved production issues, but long-term margin pressure from J&J channel.
- **Integrity Expansion**: Surgeons using existing Integrity SKUs in new anatomies; new SKUs expected to boost 2026+ sales.
- **FDA Strategy**: FDA encouraged submission of Hyalofast full data package, including secondary endpoints and international studies, under Breakthrough Devices program.
- **Cash Management**: Operating cash flow improving, capex focused on supporting growth in Integrity, Cingal, and Hyalofast.


Anika Therapeutics, Inc. (ANIK) Q2 2025 Earnings Call Transcript

- **Commercial Channel Strength**: 18% YoY growth driven by 33% regenerative solutions expansion and 13% international OA pain gains.
- **Integrity Momentum**: 300+ surgeries in Q1, targeting >2x 2024 procedures with new foot/ankle geometries.
- **Hyalofast & Cingal Progress**: Hyalofast PMA module 2 filed on time; Cingal bioequivalence study path confirmed, with NDA filing pending completion.
- **Financial Challenges**: OEM channel down 23% Q1 due to U.S. pricing, with 2025 EBITDA guidance adjusted to -3% to +3%.
- **Cash Management**: $53M on hand; sufficient liquidity for 2025 initiatives.

**【CEO Opening Remarks】**
- Q1 2025 revenue: $26.2M (-10% YoY), driven by 23% decline in OEM channel due to U.S. pricing pressure. Commercial channel grew 18% YoY, with international OA pain up 13% and regenerative solutions up 33%.
- Key achievements: 
  - Integrity sales grew 33% YoY, with 300+ surgeries in Q1 and >1% market share of U.S. soft tissue augmentation.
  - Hyalofast PMA module 2 filed on time; Cingal bioequivalence study path confirmed with FDA.
  - Operating expenses down 12% YoY, with $4M+ cost savings.

**【CFO Financial Review】**
- Gross margin: 56% (-9ppt YoY) due to lower J&J sales and production inefficiencies. Q2 gross margin expected to stabilize, with H2 targeting 58-59%.
- OpEx: $19M (-12% YoY), with SG&A down 14% and R&D down 5%.
- Cash: $53M at end of Q1; $4M share buyback completed, with no further updates on remaining $11M.
- 2025 guidance: 
  - Commercial channel: $47-49.5M (12-18% growth)
  - OEM channel: $62-65M (-16-20% YoY)
  - Adjusted EBITDA: -3% to +3% (vs. prior 8-10% range) due to pricing, manufacturing, and Cingal study costs.

**【Q&A Highlights】**
1. **Cingal Bioequivalence Study**: 
   - Study to begin by end-2025; NDA filing contingent on successful completion.
   - 2025 costs: ~0.5ppt EBITDA impact.
2. **OEM Channel Outlook**: 
   - Sequential Q2 improvement expected due to pricing rebound, but full-year decline of 18% anticipated.
3. **Integrity Growth**: 
   - 300+ surgeries in Q1, targeting >2x 2024 procedures. New foot/ankle geometries launching in 2025.
4. **Hyalofast Regulatory Path**: 
   - Module 3 filing expected by end-2025; U.S. launch in 2026.
5. **Cash Position**: 
   - Sufficient funds for regulatory efforts; no immediate need for additional capital.

Anika Therapeutics (ANIK)-9 May 25-2025 Q1 Earnings call transcript

- **Revenue Resilience**: Q4 2024 revenue growth (+1% YoY) driven by commercial channel expansion
- **Integrity Breakthrough**: 3rd consecutive quarter of >40% sequential growth, clinical data showing no retears at 6 months
- **Strategic Restructuring**: Parcus Medical divestiture finalized, focusing resources on high-margin HA products
- **Pipeline Momentum**: Hyalofast U.S. launch in 2026, Cingal bioequivalence study progressing with FDA


**【CEO Business Highlights】**
- **Q4 2024 Revenue**: $30.6 million (+1% YoY), Full Year 2024: $119.9 million (-1% YoY)
- **Commercial Channel Growth**: +25% Q4, +17% Full Year
- **International OA Pain Management**: +22% Q4, +16% Full Year
- **Integrity Implant System**: 
  - Q4 2024 Surgeries: >300 (1,000+ globally since launch)
  - Sequential Growth: >40% for 3rd consecutive quarter
  - Clinical Data: 3-month pain reduction and 6-month strength improvement with no retears
- **Pipeline Progress**: 
  - Hyalofast PMA Module 2 filed in Q1 2025, targeting U.S. launch in 2026
  - Cingal bioequivalence study design finalized with FDA

**【CFO Financial Updates】**
- **Parcus Medical Sale**: Completed to Medacta in Q1 2025
- **Financial Impact**: 
  - Cash received at closing (subject to post-closing adjustments)
  - Transition services agreement for 2025
- **Cost Optimization**: Shifting focus to high-margin HA technologies


Actual											0.24	-0.54	-0.45	-1.1	0.2	0.45	0.04	-0.4	-0.2	-0.2	-0.29	-0.34	-0.36	0.06	0	0.05	0.09	0.17	-0.25	-0.03	-0.06	-0.13	0.04	0.31
Forecast											-0.05	-0.245	-0.01	-0.015	-0.125	-0.1467	-0.2102	-0.2833	-0.3333	-0.2267	-0.25	-0.24	-0.34	-0.32	-0.3533	-0.2267	-0.08	0.0667	0.09	-0.225	-0.09	-0.2633	-0.18	-0.125
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+580.00%	-120.41%	-4400.00%	-7233.33%	+260.00%	+406.75%	+119.03%	-41.19%	+39.99%	+11.78%	-16.00%	-41.67%	-5.88%	+118.75%	+100.00%	+122.06%	+212.50%	+154.87%	-377.78%	+86.67%	+33.33%	+50.63%	+122.22%	+348.00%

ANIK

ANIK fundamentals

ANIK Q4 2025 Earnings

Earnings Call

You can ask Aime

ANIK

ANIK fundamentals

ANIK Q4 2025 Earnings

Earnings Call

ANIK Earnings Call Summary for Q4/20258:30 AM on Feb 26, 2026

ANIK Earnings Call Summary for Q3/20258:30 AM on Nov 5, 2025

ANIK Earnings Call Summary for Q2/20258:30 AM on Jul 30, 2025

ANIK Earnings Call Summary for Q1/20258:30 AM on May 9, 2025

ANIK Earnings Call Summary for Q4/20245:00 PM on Mar 12, 2025

You can ask Aime